Corvus Pharmaceuticals (NASDAQ:CRVS) Releases Earnings Results, Misses Expectations By $0.06 EPS

Corvus Pharmaceuticals (NASDAQ:CRVS) issued its earnings results on Tuesday. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.06), Zacks reports.

Corvus Pharmaceuticals Price Performance

Shares of CRVS traded down $0.32 during mid-day trading on Tuesday, reaching $3.93. The stock had a trading volume of 1,041,060 shares, compared to its average volume of 564,653. The business’s fifty day moving average is $4.72 and its 200 day moving average is $6.10. Corvus Pharmaceuticals has a 52-week low of $1.30 and a 52-week high of $10.00. The firm has a market cap of $252.53 million, a price-to-earnings ratio of -4.23 and a beta of 0.91.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Corvus Pharmaceuticals in a report on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $12.38.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.